Biotech · Private company · Los Angeles, CA, US
Aleutian Therapeutics, Inc.
Track this companyFree. Adds Aleutian Therapeutics, Inc. to your Dealase workspace and tells you when its record changes.
Clinical trials0None registered
Pipeline programs0None found yet
Disclosed deals0None found yet
Cash runwayNot availablePrivate: no SEC financials
NIH awards3
- Development of immune evasive strategies for allogeneic cell replacement therapiesFiscal year 2025 · $307.1KNIH RePORTER 1R41AI191979-01 · fetched Nov 12, 2026
- Development of a gene edited platform to enable human allogeneic cell replacement therapyFiscal year 2025 · $305.9KNIH RePORTER 1R41AI192172-01 · fetched Nov 12, 2026
- Development of an immune evasive stem cell line for Type 1 diabetes regenerative therapyFiscal year 2025 · $372.1KNIH RePORTER 1R41DK142395-01 · fetched Nov 12, 2026